- Home
- AXIL vs ELOX Comparison
AXIL vs ELOX Comparison
Compare AXIL & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXIL | ELOX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5M | 41.0M |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AXIL | ELOX |
|---|---|---|
| Price | $6.24 | $15.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 35.0K | ★ 36.2K |
| Earning Date | 04-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 230.00 | 41.67 |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $30,847,570.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.79 | ★ N/A |
| Revenue Growth | ★ 17.48 | N/A |
| 52 Week Low | $4.28 | $10.00 |
| 52 Week High | $9.86 | $23.40 |
Technical Indicators
Market Signals| Indicator | AXIL | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 41.25 |
| Support Level | $5.79 | $10.74 |
| Resistance Level | $7.38 | $14.37 |
| Average True Range (ATR) | 0.53 | 2.62 |
| MACD | 0.06 | -0.67 |
| Stochastic Oscillator | 43.53 | 2.95 |
Price Performance
Historical ComparisonAbout AXIL AXIL Brands Inc.
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, and outdoor speakers, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering. The company operates two operating segments: hearing enhancement and protection, and hair and skin care.
About ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.